![Tomas Navratil](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Tomas Navratil
Corporate Officer/Principal bei
GLAUKOS CORPORATION
Vermögen: 9 Mio $ am 31.05.2026
Profil
Dr. Tomas Navratil is a Chief Development Officer at Glaukos Corp.
He is on the Board of Directors at Severomoravske Vodovody a Kanalizace Ostrava as.
Dr. Navratil was previously employed as an Executive VP, Global Head-Research & Development by Nicox SA, a Senior Vice President-Development by Envisia Therapeutics, Inc., a Director-Medical & Scientific Affairs by Inspire Pharmaceuticals, Inc., a General Manager by Nicox Ophthalmics, Inc., and an Executive Director-Clinical Research by Parion Sciences, Inc. He received his undergraduate degree from The University of North Carolina at Charlotte and a doctorate degree from The University of North Carolina at Charlotte.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
GLAUKOS CORP 0,15 % | 16.06.2026 | 88 833 ( 0,15 % ) | 9 Mio $ | 31.05.2026 |
Aktive Positionen von Tomas Navratil
| Unternehmen | Position | Beginn |
|---|---|---|
| GLAUKOS CORPORATION | Corporate Officer/Principal | 01.04.2022 |
Severomoravske Vodovody a Kanalizace Ostrava as
 Severomoravske Vodovody a Kanalizace Ostrava as Water UtilitiesUtilities Engages in supply of drinking water and sewage services | Direktor/Vorstandsmitglied | - |
Ehemalige bekannte Positionen von Tomas Navratil
| Unternehmen | Position | Ende |
|---|---|---|
Nicox Ophthalmics, Inc.
 Nicox Ophthalmics, Inc. Pharmaceuticals: MajorHealth Technology Manufactures ophthalmology pharmaceutical products | Corporate Officer/Principal | - |
Inspire Pharmaceuticals, Inc.
 Inspire Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes ophthalmic products | Technik-/Wissenschafts-/F&E-Leiter | - |
| NICOX SA | Technik-/Wissenschafts-/F&E-Leiter | - |
Parion Sciences, Inc.
 Parion Sciences, Inc. Miscellaneous Commercial ServicesCommercial Services Develops new treatments for serious diseases in multiple therapeutic areas | Corporate Officer/Principal | - |
Envisia Therapeutics, Inc.
 Envisia Therapeutics, Inc. BiotechnologyHealth Technology Develops novel ocular therapies | Corporate Officer/Principal | - |
Ausbildung von Tomas Navratil
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
21
Beziehungen ersten Grades
8
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 8 |
|---|---|
Inspire Pharmaceuticals, Inc.
Inspire Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes ophthalmic products | Health Technology |
Parion Sciences, Inc.
Parion Sciences, Inc. Miscellaneous Commercial ServicesCommercial Services Develops new treatments for serious diseases in multiple therapeutic areas | Commercial Services |
Glaukos Corp.
 Glaukos Corp. Medical SpecialtiesHealth Technology Operates as an ophthalmic medical device company | Health Technology |
Nicox Ophthalmics, Inc.
Nicox Ophthalmics, Inc. Pharmaceuticals: MajorHealth Technology Manufactures ophthalmology pharmaceutical products | Health Technology |
Nicox SA
 Nicox SA Pharmaceuticals: MajorHealth Technology Manufactures and sells ophthalmology biopharmaceuticals | Health Technology |
Severomoravske Vodovody a Kanalizace Ostrava as
Severomoravske Vodovody a Kanalizace Ostrava as Water UtilitiesUtilities Engages in supply of drinking water and sewage services | Utilities |
The University of North Carolina at Charlotte
 The University of North Carolina at Charlotte Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Envisia Therapeutics, Inc.
Envisia Therapeutics, Inc. BiotechnologyHealth Technology Develops novel ocular therapies | Health Technology |
